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The purpose of the study was to investigate the toxicity and efficacy of the combination of gemcitabine and docetaxel in untreated
advanced urothelial carcinoma. Patients with previously untreated, locally advanced/recurrent or metastatic urothelial carcinoma
stage-IV disease were eligible. Patients with Performance status: PS ECOG 43 or age 475 years or creatinine clearance
o50mlmin
 1 were excluded. Study treatment consisted of docetaxel 75mgm
 2 (day 8) and gemcitabine 1000mgm
 2 (days
1þ8), every 21 days for a total of six to nine cycles. A total of 31 patients with urothelial bladder cancer, 25 men and six women,
aged 42–74 (median 64) years were enrolled. The majority of patients had a good PS (51.6%; PS 0). In all, 15 (48.3%) patients had
locally advanced or recurrent disease only and 16 (54.8%) presented with distant metastatic spread, with multiple site involvement in
22.5%. Toxicity was primarily haematologic, and the most frequent grade 3–4 toxicities were anaemia 11 (6.7%) thrombocytopenia
eight (4.9%), and neutropenia 45 (27.6%), with 10 (6.1%) episodes of febrile neutropenia. No toxic deaths occurred. A number of
patients had some cardiovascular morbidity (38.7%). Nonhaematological toxicities except alopecia (29 patients) were mild. Overall
response rate was 51.6%, including four complete responses (12.9%) and 12 partial responses (38.7%), while a further five patients
had disease stabilisation (s.d. 16.1%). The median time to progression was 8 months (95% CI 5.1–9.2 months) and the median overall
survival was 15 months (95% CI 11.2–18.5 months), with 1-year survival rate of 60%. In conclusion, this schedule of gemcitabine and
docetaxel is very active and well tolerated as a first-line treatment for advanced/relapsing or metastatic urothelial carcinoma. Although
its relative efficacy and tolerance as compared to classic MVAC should be assessed in a phase III setting, the favourable toxicity profile
of this regimen may offer an interesting alternative, particularly in patients with compromised renal function or cardiovascular disease.
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Although advanced urothelial carcinoma is a common and
relatively chemosensitive neoplasm, it still remains a fatal disease.
Over the last 10 years or so chemotherapy of advanced urothelial
tumours has focused on cisplatin-based combinations such as
cisplatin–methotrexate–vinblastine (CMV), or methotrexate–
vinblastine–adriamycin–cisplatin (M-VAC) (von der Maase,
2002). Response rates with standard cisplatin-based combination
chemotherapy range from 40 to 70%; however, approximately 50%
of all patients will develop metastasis, and recent studies indicate
that the disease-free long-term (5-year) survival rate is only about
4% (Sternberg et al, 1989; Loehrer et al, 1992; Saxman et al, 1997).
Standard therapy with M-VAC offers a moderate median survival
of 1 year; however, it is achieved at the expense of major toxicities,
including myelosuppression, nausea, vomiting and nephrotoxicity
that often limit its use to patients with normal renal function and
adequate performance status (Vaughn, 1999). A recent phase III
study has indicated that the combination of gemcitabine/cisplatin
could replace the standard of care M-VAC (von der Maase et al,
2000; Hussain et al, 2002; de Wit, 2003; Raghavan, 2003) since the
efficacy was similar in the two regimens with respect to response,
time to progressive disease and overall survival; however, toxicity
was significantly less in the gemcitabine/cisplatin arm (von der
Maase et al, 2000). Owing to the discouraging long-term survival
data for M-VAC and gemcitabine/cisplatin, attempts at minimising
toxicity and maintaining current median survival times are
recognised as important considerations in patient management
since palliation appears to be a current goal for urothelial cancer.
Therefore, research is now focusing on new regimens including
a series of agents that may improve the efficacy of established
therapies, while also being effective in the subgroups of patients in
which cisplatin-based regimens are contraindicated. Recent studies
have indicated that the taxanes (docetaxel and paclitaxel) have
significant antitumour activity as single agents (Roth et al, 1994;
Dreicer et al, 1996; McCaffrey et al, 1997; Papamichael et al, 1997),
or when administered in combination with other drugs (Redman
et al, 1998; Zielinski et al, 1998; Bajorin et al, 2000; Dreicer et al,
2000; Hussain et al, 2001), in urothelial cancer. The majority of
these new agents have demonstrated synergy when used in
combination with a platinum salt showing encouraging response
rates of up to 50% and median survival times of 9–14.3 months are
reported across a range of combinations (Redman et al, 1998;
Zielinski et al, 1998; von der Maase et al, 1999; Dreicer et al, 2000;
Kaufman et al, 2000a; Lorusso et al, 2000; Small et al, 2000).
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sWe have therefore decided to investigate the efficacy and
toxicity of the combination of docetaxel and gemcitabine in
chemonaive patients with locally advanced or metastatic urothelial
carcinoma.
PATIENTS AND METHODS
Patient selection
This was a phase II study in patients with histologically confirmed
advanced urothelial cancer. Patients with locally advanced or
metastatic cancer of the urothelial tract with transitional cell
histologies, and with evidence of measurable or evaluable disease
were eligible. No previous chemotherapy for recurrent disease was
allowed. Previous neoadjuvant or adjuvant treatment was allowed
as long as there was at least a 12-month treatment-free interval and
gemcitabine was not part of the previous chemotherapy combina-
tion (previous treatment with docetaxel as part of adjuvant or
neoadjuvant chemotherapy was allowed provided X12 months
had passed).
Patients with other malignant tumour or tumour history, except
for nonmelanoma skin cancer or radically excised in situ
carcinoma of the uterine cervix were excluded. Patients aged
475 years were excluded, as were patients with severe chronic
obstructive lung disease. Also excluded were patients with known
CNS metastases, patients who were pregnant or those with
creatinine clearance less than 50mlmin
 1, WBC o3.5 10
9l
 1,
neutrophil count o1.5 10
9l
 1 or platelet count o100 10
9l
 1
within the 2 weeks preceding the start of the study. Furthermore,
patients with active infections or other serious underlying medical
or mental conditions, which would impair their ability to receive
protocol treatment, could not participate.
The study was conducted according to the Declaration of
Helsinki and the guidelines for Good Clinical Practice. The local
ethics committees approved the protocol and informed consent
was obtained from all patients prior to study entry.
Treatment schedule
Treatment was administered on an outpatient basis. Gemcitabine
1000mgm
 2 was administered by an intravenous infusion over
30min on days 1 and 8, while docetaxel (75mgm
 2) was
administered as an intravenous infusion over 1h on day 8.
Treatment was repeated every 21 days. Standard antiemetic
premedication and treatment was administered. Haematopoietic
growth factors were not used prophylactically. Supportive care,
including blood transfusions, analgesics and antiemetics, was
administered as appropriate. Patients received a total of six cycles
unless disease progression or unacceptable toxicity occurred.
Patients who showed disease stabilisation or response were
scheduled to receive the same regimen for up to nine full
chemotherapy cycles.
Dose modifications for adverse events
Toxicity was evaluated before each treatment cycle according to
the National Cancer Institute Common Toxicity Criteria (NCI CTC
version 2.0). Dosage adjustments were made before each treatment
based on blood counts, renal and liver function tests and other
toxicity. Once the dose of chemotherapy was reduced, they were
not re-escalated. Both drugs were given on schedule providing that
ANC was X1.5 10
9l
 1 and the platelet count X100 10
9 l
 1.
For ANC of o1.5 10
9l
 1 on day 1, treatment was delayed for 1
week, haematopoietic growth factor (G-CSF) 5 days were given,
and the next cycle began on day 28 instead of day 21. If platelet
counts were o75 10
9l
 1 for 1 week, the next cycles were to be
given every 4 weeks. If platelets were o75 10
9l
 1 for 2 weeks,
then the next cycles were to be given every 4 weeks with the doses
of both drugs reduced by 25%. If ANC did not recover above
1.5 10
9l
 1 for 3 weeks or if platelets were o75 10
9l
 1 for 42
weeks, treatment was discontinued and the patient was taken off
study. In case of haematological toxicity on day 8 (AN-
Co1.5 10
9l
 1, PLTo100 10
9l
 1), the gemcitabine treatment
of day 8 was delayed for 1 week. The same dose was then
administered on day 15, and the cycle was repeated every 28 days
instead of 21 days. In case of persistent haematological toxicity on
day 15, the gemcitabine day 8 treatment was omitted and
chemotherapy was repeated on day 21 with a 25% dose reduction
for both drugs. In case of grade 3–4 neutropenia during a
chemotherapy cycle, G-CSF 5 days was to be used prophylacti-
cally for the next cycles, days 10–14.
Evaluation of response
Baseline evaluation prior to chemotherapy initiation included a
complete past medical history, thorough physical examination, a
chest X-ray followed by CT scan of the chest if CXR was abnormal,
a CT scan of the abdomen and pelvis, bone scan, as well as
complete blood counts, renal and liver function tests. During
treatment, renal and liver function tests were carried out before
each cycle on day 1, and complete blood count was carried out on
days 1 and 8 of each cycle. Complete blood counts were also
obtained on day 14 of the first course in order to assess nadir WBC
and PLT.
Restaging and tumour measurements were performed after three
cycles and following completion of treatment, that is, after six or
nine cycles of chemotherapy, unless earlier evaluation was
required. Dose intensity was defined as the total amount of the
drug given (mgm
 2) divided by the number of weeks. All patients
were analysed on an intention-to-treat basis. Therefore, all
patients, even those receiving only one cycle of chemotherapy,
were analysed for toxicity, response, duration of response and
survival. Patients who discontinued treatment before an evaluation
was performed were rated as nonresponders. Standard WHO
criteria were used to assess response.
Treatment was discontinued if disease progression was docu-
mented, or when unacceptable toxicity or conditions requiring
therapeutic intervention not permitted by the protocol occurred.
Also, treatment was discontinued when the patient wished to
withdraw consent, or in any other situation where, in the opinion
of the investigator continued participation in the study would not
be in the best interest of the patient. All adverse events resulting in
discontinuation of study drug were followed closely until
resolution or stabilisation. Follow-up disease evaluation was
performed regularly at 3 monthly intervals after treatment
completion till death. Progression or disease relapse, surgical
procedures (cystectomy, etc.), site of relapse and cause of death
were noted.
Statistical analysis
The study was a nonrandomised, phase II study. The primary end
point was objective response rate and secondary end points were
overall survival, TTP and toxicity. The sample size was calculated
on the assumption that a 40% response rate would be detected and
the minimum acceptable response rate would be 20%. According
to Simon’s two-stage design, a sample of 18 patients was required
in the first step. If a minimum of five responses were observed, a
total of 33 patients would be accrued. Thereby, if at least 11
responses occurred, the probability of accepting a treatment with a
real response rate of less than 20% would be 5%. On the other
hand, the risk of rejecting a treatment (at the second stage) with a
response rate of more than 40% would be 20%. Time to disease
progression (TTP) was calculated from the initiation of treatment
to the date progression of the disease was firstly documented
(patients who discontinued their treatment for any reason or died
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time, as having disease progression). Survival was calculated from
initiation of treatment to the date of last contact or to the date of
death. The Kaplan–Meier method (Kaplan and Meier, 1958) was
used to calculate TTP and survival curves and exact CIs (Lentner,
1982) were used to determine the 95% upper and lower confidence
limits of response rate. Data analysis was performed using SPSS
10.5 (SPSS, Inc, Chicago, IL, USA).
RESULTS
Patient characteristics
Between May 2000 and April 2002, 31 patients with locally
advanced/relapsed or metastatic urothelial carcinoma of stage IV
were accrued to this single-institution study. Two patients could
not be evaluated for efficacy end points since they were lost to
follow-up after two and three cycles, respectively. Final data
analysis was performed in May 2003, 12 months after accrual of the
last patient. The main patient baseline characteristics are
summarised in Table 1. The majority of patients had ECOG
Performance Status of 0 or 1; only 9.7% of the patients had a PS of
2. A percentage of the patients (12; 38.7%) had some type of
coexisting cardiovascular disease.
More than half of the patients presented with distant metastases,
while among the remaining 15 patients, five (16.1%) had locally
recurrent and 10 (32.2%) had de novo locally advanced disease.
The total number of patients with disease in the pelvis was 20
(64.5%). Eight (25.8%) patients presented both local and distant
disease, with multiple site involvement in seven (22.5%) patients.
Study treatment was administered in all cases as first-line therapy;
however, while 14 patients had not previously received any
therapeutic manipulation, 16 patients had prior surgery, eight
patients were exposed to prior adjuvant/neoadjuvant chemother-
apy, or radiotherapy (n¼8) to the pelvis. Eight patients had
previously received chemotherapy in the adjuvant or neoadjuvant
setting; two with M-VAC, one with MVEC, two with CMV, one with
CisCA and two with carboplatin/gemcitabine.
Study treatment administration
All patients were included in the analysis of treatment adminis-
tration and toxicity. A total of 163 treatment cycles were
administered. Patients received a median number of six cycles of
chemotherapy, with a range of one to nine cycles. Of the 31
patients analysed, 20 patients (64.5%) completed at least six cycles
of treatment, and six (19.4%) received seven to nine cycles.
Reasons for treatment discontinuation included disease progres-
sion or recurrence in eight patients. Dosage of study drugs was
modified mainly due to haematological toxicity. A total of 20
patients received G-CSF. Gemcitabine doses were reduced (dose
actually taken p90% of planned dose) or omitted on day 1 in 15
(9.2%) cycles and on day 8 in nine (5.5%) courses. The median
delivered dose intensity was 599.4mgm
 2week
 1 (range: 580–
633mgm
 2) for gemcitabine, and 20.2mgm
 2week
 1 for doc-
etaxel (range: 15–25mgm
 2), with a mean relative dose intensity
of 90 and 95% for gemcitabine and docetaxel, respectively. All five
patients with bone metastasis received pamidronate 90mg every
3–4 weeks for 6–12 months to achieve palliation of skeletal
symptoms.
Toxicity
All patients (n¼31) were evaluable for toxicity. Toxicity was
primarily haematologic with neutropenia being the most promi-
nent with 33 incidences of grade 3 and 12 of grade 4. There were 10
episodes of grade 4 febrile neutropenia requiring hospitalisation.
No toxic deaths occurred. Nonhaematological toxicities were mild,
23 episodes of hypersensitivity and/or cutaneous reactions grade 3/
4. Alopecia occurred in nearly all patients. Grade 3–4 toxicity data
according to the NCI CTC criteria are summarised in Table 2.
Table 1 Patient characteristics
Patients
Characteristic No. %
Number of patients registered 31
Age, years
Median 64
Range 42–74
Sex
Male 25 80.6
Female 6 19.4
Performance Status ECOG
0 16 51.6
1 12 38.7
2 3 9.7
Cardiovascular comorbidity
Hypertension (controlled) 18 58
Atherosclerosis 11 35.5
Coronary artery disease 7 22.5
Total (one or a combination of the above) 12 38.7
Histological types
Transitional cell carcinoma 31 100
Previous treatment
Surgery 16 51.6
Chemotherapy 8 25.8
Radiotherapy 8 25.8
Sites of disease
Locally advanced disease 10 32.2
Locally recurrent 5 16.1
Metastatic disease 16 51.6
Lymph nodes 7 22.5
Bones 5 16.1
Lung 9 29.0
Liver 7 22.5
Multiple site involvement 7 22.5
Local and distant disease 8 25.8
Note: patients can have more than one site of metastatic disease.
Table 2 Toxicity (cycles n¼163)
Grade 3 Grade 4
Toxicity No. % No. %
Anaemia 11 6.7 0 0
Neutropenia 33 20.2 12 7.4
Thrombocytopenia 6 3.7 2 1.2
Diarrhoea 10 6.1 0 0
Febrile neutropenia 0 0 10 6.1
Cutaneous 11 6.7 3 1.8
Hypersensitivity 9 5.5 0 0
Fever 9 5.5 0 0
Oedema 8 4.9 0 0
Mucositis 7 4.3 1 0.6
Percentages expressed per cycle.
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From a total of 31 patients entered in the study, two were lost to
follow-up, however, due to the intention-to-treat-analysis; all of the
patients enrolled were included in the main analysis of the
response rate; Table 3. Four patients achieved a complete response
(CR 12.9%) and 12 patients achieved a partial response (PR
38.7%), giving an overall response (OR) of 51.6%. In addition, five
patients achieved disease stabilisation (s.d. 16.1%), while eight
patients had progressive disease (PD 25.8%). Responses were seen
at all sites of measurable disease. Skeletal sites were not included in
the response assessment given the concurrent use of pamidronate,
although in all five patients with bone metastases a symptomatic
palliation as well as evidence of stabilization (three patients) or
bone healing (two patients) were noted.
With a median follow-up of 23 months (range 12–36 months),
26 patients have died (83.9%). The median time to progression
(TTP) was 8.0 months (range 0.0–20.0, 95% CI: 5.1–9.2). With five
patients still alive, two at 36þ months the median survival has not
been reached; 15 months (range 2.0–36.0þ, 95% CI: 11.2–18.5).
The estimated 1-year survival rate was 60% (Figure 1).
DISCUSSION
In this phase II trial, the combination of gemcitabine and docetaxel
was well tolerated and effective as first-line treatment for
metastatic urothelial carcinoma. The OR rate of 51.6% and a
median overall survival of 15 months were similar to a series of
rates achieved with combinations including cisplatin/gemcitabine
(Moore et al, 1999; von der Maase et al, 1999; Kaufman et al,
2000a; Lorusso et al, 2000) or cisplatin/docetaxel (Sengelov et al,
1998; Dimopoulos et al, 1999).
For many years the gold standard treatment for urothelial
cancer has been the M-VAC regimen. However, with the results of
the recent randomised comparison with gemcitabine/cisplatin,
options are rapidly changing (von der Maase, 2002). It has been
realised that using alternative two or three drug combination
regimens principally utilising platinum salts, efficacy with respect
to disease-free survival, time to progression and overall survival
can be maintained while reducing not only the toxicity but also
improving the overall quality of life (Sternberg, 2000). There are,
however, concerns with the use of platinum salts, as the toxicities
are not insignificant especially considering that long-term survival
remains relatively poor and the major clinical benefit for the move
away from M-VAC is palliative rather than curative. As many
patients are unable to tolerate cisplatin-based therapy, carboplatin
has been investigated as an alternative. Although it has found its
way into clinical use due to a low toxicity profile, when compared
to standard M-VAC, trials indicate disappointing single-agent
response rates (Medical Research Council, 1987) and shorter
median survival when combined with paclitaxel (Redman et al,
1998; Vaughn et al, 1998). In the few studies that have been
published, the combination of carboplatin/gemcitabine appears to
be inferior to that obtained with gemcitabine/cisplatin (Stadler,
2002; von der Maase, 2002).
Although few studies have investigated the combination of
gemcitabine/paclitaxel, the so far reported small phase II trials
have indicated that the combination is effective and well tolerated.
In a phase II study using 2500–3000mgm
 2 gemcitabine and
150mgm
 2 paclitaxel every 2 weeks in M-VAC-pretreated
patients, Marini et al (1999) reported an overall response rate of
62% and complete response of 24%. Neutropenia grade 3/4 was
noted in 43% and neurotoxicity in 6% of the patients. In the
studies by Sternberg et al (2000) and Kaufman et al (2000b),
combination of 3000mgm
 2 gemcitabine and 150mgm
 2 pacli-
taxel was delivered every 2 weeks in previously treated and
chemonaive patients, respectively. They reported OR rates of 39
and 64% (CR 25%), respectively. In a further study by Meluch et al
(2001), gemcitabine was administered on days 1, 8 and 15 at
1000mgm
 2 and paclitaxel at 200mgm
 2 on day 1 every 21 days.
In all, 29 of 54 eligible patients responded (54%), 22 in the group of
42 patients with no prior chemotherapy, with a CR rate of 7%.
Grade 3/4 neutropenia was observed in 46% and grade 3/4
thrombocytopenia was seen in 13% of the patients.
As for the combination of gemcitabine/docetaxel in urothelial
cancer, only one report has been published in which three out of
five patients developed pulmonary toxicity in a phase I setting
(Dunsford et al, 1999). In our patients no clinically significant
toxicity was detected, although there might have been some
subclinical decrease of respiratory reserve. However, none of our
patients had a history of lung disease except for smoking, continued
or in the past, in 19 patients. Nevertheless, the risk of pulmonary
toxicity must be kept in mind when treating patients with this
combination. The absence of cardiovascular complications in this
population, although not expected with the gemcitabine/docetaxel
combination, has to be emphasised, since a significant proportion
of patients presented with some heart or arterial disease.
To our knowledge, the present clinical trial represents one of the
first phase II studies using this combination showing an OR of
51.6% and CR of 12.9% comparable with other studies in
chemotherapy naı ¨ve patients, albeit mainly using the combination
of gemcitabine/paclitaxel. Moreover, one recent phase II study has
investigated the combination of gemcitabine/docetaxel in TCC
with a different schedule and found a lower objective response rate
(33.3%) but a similar overall (52 weeks) survival (Gitliz et al, 2003).
The taxanes are primarily being studied due to their efficacy in
previously pretreated patients. Incorporation of taxanes as first-
line treatment for advanced urothelı ´al carcinoma may not only
Table 3 Response and survival (n¼31)
No. %
Complete response (CR) 4 12.9
Partial response (PR) 12 38.7
Stable disease (SD) 5 16.1
Progressive disease (PD) 8 25.8
Overall response (OR) 16 51.6
Median (months) 95% CI
Time to progression 8.0 5.1–9.2
Overall survival 15 11.2–18.5
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Figure 1 Time to progression (TTP) and overall survival.
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indicated as a first-line treatment, if equivalence to M-VAC or
gemcitabine/cisplatin regimens can be confirmed by further
studies. At present the choice of effective regimens needs to be
addressed by more rigorous patient stratification and comparison
with M-VAC or gemcitabine/cisplatin in both naı ¨ve and previously
pretreated patients, while special attention should be paid towards
compromised patients.
In conclusion, the efficacy of the gemcitabine/docetaxel regimen
reported in this study coupled with the acceptable toxicity
observed indicate that this combination is an interesting candidate
for future comparisons with M-VAC or other gemcitabine- or
cisplatin-based regimens. Furthermore, the favourable toxicity
profile indicates it as an interesting alternative, particularly in
patients with compromised renal function or cardiovascular
disease.
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